Greenspan S L, Greenspan F S
Division of Bone and Mineral Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA.
Ann Intern Med. 1999 May 4;130(9):750-8. doi: 10.7326/0003-4819-130-9-199905040-00016.
Thyroid disease and osteoporosis are common problems often managed by primary care physicians. Despite many studies, confusion still exists about the effect of thyroid hormone on skeletal health.
To review evidence on the effect of thyroid hormone (from hyperthyroidism, exogenous or endogenous suppression of thyroid-stimulating hormone [TSH], and thyroid hormone replacement therapy) on skeletal integrity.
A MEDLINE search of papers published between 1966 and 1997.
Cross-sectional studies, longitudinal studies, and meta-analyses that had appropriate control groups (patients matched for age, sex, and menopausal status), made comparisons with established databases, or defined thyroid state by TSH level or thyroid hormone dose were reviewed.
Data synthesis was not straightforward because of changes in doses and types of thyroid hormone preparations; changes in definitions of thyroid hormone replacement therapy and suppressive therapies; problems with study design; differences in skeletal sites assessed (hip, spine, forearm, or heel) and techniques used to measure bone mineral density; and inclusion of heterogenous and changing thyroid disease states. Overall, hyperthyroidism and use of thyroid hormone to suppress TSH because of thyroid cancer, goiters, or nodules seem to have an adverse effect on bone, especially in postmenopausal women; the largest effect is on cortical bone. Thyroid hormone replacement seems to have a minimal clinical effect on bone.
Women with a history of hyperthyroidism or TSH suppression by thyroid hormone should have skeletal status assessed by bone mineral densitometry, preferably at a site containing cortical bone, such as the hip or forearm.
甲状腺疾病和骨质疏松症是常见问题,通常由初级保健医生处理。尽管有许多研究,但甲状腺激素对骨骼健康的影响仍存在困惑。
综述甲状腺激素(来自甲状腺功能亢进、外源性或内源性促甲状腺激素[TSH]抑制以及甲状腺激素替代疗法)对骨骼完整性影响的证据。
对1966年至1997年间发表的论文进行医学文献数据库(MEDLINE)检索。
回顾了具有适当对照组(年龄、性别和绝经状态匹配的患者)、与既定数据库进行比较或通过TSH水平或甲状腺激素剂量定义甲状腺状态的横断面研究、纵向研究和荟萃分析。
由于甲状腺激素制剂的剂量和类型变化、甲状腺激素替代疗法和抑制疗法定义的变化、研究设计问题、评估骨骼部位(髋部、脊柱、前臂或足跟)的差异以及用于测量骨密度的技术不同,以及纳入了异质性且不断变化的甲状腺疾病状态,数据综合并不简单。总体而言,甲状腺功能亢进以及因甲状腺癌、甲状腺肿或结节而使用甲状腺激素抑制TSH似乎对骨骼有不良影响,尤其是在绝经后女性中;对皮质骨的影响最大。甲状腺激素替代似乎对骨骼的临床影响最小。
有甲状腺功能亢进病史或因甲状腺激素导致TSH抑制的女性,应通过骨密度测定评估骨骼状态,最好在含有皮质骨的部位,如髋部或前臂。